New phase 3 results should reopen discussion about the off-label use of COMT inhibitors in early Parkinson's disease, experts ...

An experimental first-in-class oral selective partial D1/D5 dopamine receptor agonist for Parkinson's significantly reduce ...

Amneal is releasing Crexont (carbidopa and levodopa) extended-release capsules for the treatment of Parkinson’s disease.

Semaglutide, the same compound that’s in Ozempic, is part of a class of medications known as glucagon-like peptide 1 (GLP-1) ...

The results of these findings were recently published in Molecular Psychiatry. Treatment of Parkinson's disease is in large part based on the administration of levodopa. The use of this drug is ...

Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN), a biopharmaceutical company focused on developing and commercializing products for the treatment of central nervous system (CNS) diseases, today ...

IRLAB Therapeutics AB , a company discovering and developing novel treatments for Parkinson's disease, today announced that dosing has been initiated in a Phase I clinical study of the drug candidate ...

Inside the 'MAHA' Movement This week, STAT reports on Calley Means and Casey Means, MD, siblings and chronic disease ...

Supernus Pharmaceuticals, Inc. has announced that it will host a webcast and conference call on October 17, 2024, at 4:30 p.m ...

Anticholinergics were used before the introduction of levodopa which is now the drug most commonly used. Dopamine agonists are effective when used alone or as an adjunct to levodopa, while monoamine ...